Lee and colleagues examined whether ctDNA levels at baseline and early during therapy could predict response and clinical outcome in metastatic melanoma patients harboring BRAF, NRAS or CKIT mutations and receiving immunotherapy [107]. Here, KIT is linked to metastatic melanoma.